The supercritical CO2 extract from the skin of Bufo bufo gargarizans Cantor blocks hepatitis B virus antigen secretion in HepG2.2.15 cells

被引:3
作者
Cui, Xiaoyan [1 ,2 ]
Inagaki, Yoshinori [2 ]
Wang, Dongliang [2 ]
Gao, Jianjun [2 ]
Qi, Fanghua [2 ]
Gao, Bo [3 ]
Kokudo, Norihiro [2 ]
Fang, Dingzhi [4 ]
Tang, Wei [2 ,4 ]
机构
[1] Tongji Univ, Tongji Hosp, Translat Ctr Stem Cell Res, Sch Med,Dept Regenerat Med, Shanghai 200092, Peoples R China
[2] Univ Tokyo, Grad Sch Med, Dept Surg, Hepato Biliary Pancreat Surg Div,Bunkyo Ku, Tokyo 1138655, Japan
[3] Anhui China Resources Jinchan Pharmaceut Co Ltd, Huaibei, Anhui, Peoples R China
[4] Sichuan Univ, West China Sch Preclin & Forens Med, Dept Biochem & Mol Biol, Chengdu 610064, Sichuan, Peoples R China
关键词
Hepatitis B virus; traditional Chinese medicine; Bufo bufo gargarizans Cantor; HepG2.2.15; cells; CHEMICAL-CONSTITUENTS; IN-VITRO; CHINA; IDENTIFICATION; INFECTION;
D O I
10.5582/bst.8.38
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
The skin of Bufo bufo gargarizans Cantor has long been used for the treatment of hepatitis B in China and supercritical carbon dioxide extraction (SC-CO2) is widely used in extracting active ingredients from natural products. The aim of present study was to assess the anti-hepatitis B virus (HBV) effect of the supercritical CO2 extract from the skin of Bufo bufo gargarizans Cantor (SCE-BC). Cytotoxicity of SCE-BC was analyzed using an MTT [3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide] assay in HepG2.2.15 cells. The hepatitis B surface antigen (HBsAg), hepatitis B e antigen (HBeAg), and hepatitis B core-related antigen (HBcrAg) concentrations in cell culture medium were determined by chemiluminescent enzyme immunoassay. HBV mRNA in cells was determined using real-time polymerase chain reaction. SCE-BC concentrations below 10(-2) mu g/mL had no significant toxicity to HepG2.2.15 cells. SCE-BC at 10(-4) mu g/mL effectively inhibited the secretion of HBeAg by 23.36% on day 6. It was more potent than the positive control lamivudine (100 mu g/mL) in terms of the inhibition of HBeAg and HBcrAg secretion on day 6. Consistent with the HBV antigen reduction, HBV mRNA expression was markedly inhibited in comparison to the control when HepG2.2.15 cells were treated with SCE-BC. Moreover, SCE-BC had greater inhibitory activity with respect to HBeAg than to HBsAg. Since HBeAg promotes immune tolerance and persistent infection during HBV infection, the present results suggest that immune tolerance induced by HBeAg might be overcome by SCE-BC. Therefore, SCE-BC warrants further investigation.
引用
收藏
页码:38 / 44
页数:7
相关论文
共 24 条
[1]   Simvastatin potentiates the anti-hepatitis B virus activity of FDA-approved nucleoside analogue inhibitors in vitro [J].
Bader, Ted ;
Korba, Brent .
ANTIVIRAL RESEARCH, 2010, 86 (03) :241-245
[2]   PHARMACOLOGY AND TOXICOLOGY OF TOAD VENOM [J].
CHEN, KK ;
KOVARIKOVA, A .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1967, 56 (12) :1535-+
[3]   Anti-hepatitis B Virus Activities of Cinobufacini and Its Active Components Bufalin and Cinobufagin in HepG2.2.15 Cells [J].
Cui, Xiaoyan ;
Inagaki, Yoshinori ;
Xu, Huanli ;
Wang, Dongliang ;
Qi, Fanghua ;
Kokudo, Norihiro ;
Fang, Dingzhi ;
Tang, Wei .
BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2010, 33 (10) :1728-1732
[4]  
Cui XY, 2010, BIOSCI TRENDS, V4, P39
[5]  
Dai Li-ping, 2007, Yaoxue Xuebao, V42, P858
[6]   Antiviral therapy for hepatitis B virus infections: new targets and technical challenges [J].
Feld, J ;
Locarnini, S .
JOURNAL OF CLINICAL VIROLOGY, 2002, 25 (03) :267-283
[7]   Characterization of Genotype-Specific Carboxyl-Terminal Cleavage Sites of Hepatitis B Virus e Antigen Precursor and Identification of Furin as the Candidate Enzyme [J].
Ito, Kiyoaki ;
Kim, Kyun-Hwan ;
Lok, Anna Suk-Fong ;
Tong, Shuping .
JOURNAL OF VIROLOGY, 2009, 83 (08) :3507-3517
[8]  
JI GS, 2005, CHIN J INTEGR TRADIT, V15, P53
[9]   Quantitative detection of hepatitis B virus by transcription-mediated amplification and hybridization protection assay [J].
Kamisango, K ;
Kamogawa, C ;
Sumi, M ;
Goto, S ;
Hirao, A ;
Gonzales, F ;
Yasuda, K ;
Iino, S .
JOURNAL OF CLINICAL MICROBIOLOGY, 1999, 37 (02) :310-314
[10]  
LAN YN, 2002, CHIN J CLIN HEPATOL, V18, P374